艾米克斯生物制药

最新新闻

• 评级变动
  Morgan Stanley Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/3/26
• 评级变动
  BofA Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Citizens JMP Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/3/9
• A Quick Look at Today's Ratings for Immix Biopharma(IMMX.US), With a Forecast Between $24 to $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/28
• 评级变动
  Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• LifeSci Capital Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Morgan Stanley Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/3/25
• 评级变动
  H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/27
• 评级变动
  BofA Securities Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2026/6/18
• 评级变动
  H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  LifeSci Capital Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/6/17
• 评级变动
  Needham Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• LifeSci Capital Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/13
• 评级变动
  Morgan Stanley Maintains Immix Biopharma(IMMX.US) With Buy Rating, Cuts Target Price to $19
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/5/22
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)
  TipRanks · 2026/5/27
• Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Needham Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/8/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。